Accéder au contenu
Merck

SML1133

SGC-CBP30

≥98% (HPLC)

Synonyme(s) :

2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C28H33ClN4O3
Numéro CAS:
1613695-14-9
Poids moléculaire :
509.04
UNSPSC Code:
51111800
PubChem Substance ID:
329825669
NACRES:
NA.77

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

SMILES string

CC1=C(C(C)=NO1)C2=CC=C3C(N=C(CCC4=CC=C(OC)C(Cl)=C4)N3C[C@@H](N5CCOCC5)C)=C2

InChI

1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1

InChI key

GEPYBHCJBORHCE-SFHVURJKSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Catégories apparentées

Application

SGC-CBP30 has been used in immunofluorescence, to study the regulation of HAT (histone acetyltransferase) activity. It has also been used to abolish synergistic gene expression induced by transcription factors in hepatocytes.

Biochem/physiol Actions

SGC-CBP30 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC50 = 0.021 and 0.038 μM, respectively). SGC-CBP30 has little activity against other bromodomains at concentrations up to 1 mM. For full characterization details, please visit the SGC-CBP30 probe summary on the Structural Genomics Consortium (SGC) website.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
SGC-CBP30 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300.
SGC-CBP30 might serve as a therapeutic agent in treating cancer. In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 is found to decrease immune cell production of T helper cell 17 and other pro-inflammatory cytokines.

Features and Benefits

SGC-CBP30 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Other Notes

SGC-CBP30 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the SGC-CBP30 probe summary on the Chemical Probes Portal website.

hcodes

H413

Hazard Classifications

Aquatic Chronic 4

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000219413
0000219413
0000173884
0000165489
0000173884

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Transcription factor dimerization activates the p300 acetyltransferase
Ortega E, et al.
Nature, 1-1 (2018)
Clinical progress and pharmacology of small molecule bromodomain inhibitors
Theodoulou NH, et al.
Current Opinion in Chemical Biology, 33, 58-66 (2016)
Epigenetic Targets in Drug Discovery, 144-144 (2018)
Synergistic gene expression during the acute phase response is characterized by transcription factor assisted loading.
Goldstein I, et al.
Nature Communications, 8(1), 1849-1849 (2017)
Kee-Beom Kim et al.
Science advances, 8(7), eabl4618-eabl4618 (2022-02-17)
EP300, a transcription coactivator important in proliferation and differentiation, is frequently mutated in diverse cancer types, including small cell lung cancer (SCLC). While these mutations are thought to result in loss of EP300 function, the impact on tumorigenesis remains largely
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique